Coherus Files Four Petitions for Inter Partes Review of Abbvie’s Adalimumab-Related Patent

PTAB + IPR

Today, Coherus Biosciences filed four petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619 (IPR2017-00822IPR2017-00823, IPR2017-00826, and IPR2017-00827).  According to the petitions, the patent is drawn to formulations of adalimumab, commercially available under the brand-name Humira®.

Coherus already has three instituted IPR proceedings on patents related to adalimumab, IPR2016-00172, IPR2016-00188, and IPR2016-00189.  These proceedings are scheduled for oral hearing on February 16, 2017.

The newly filed petitions and other important IPR documents related to biologics are posted on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.